Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
KRN1493
DRUG
3 trials
Sponsors
Seoul National University Hospital
, Kyowa Kirin Co., Ltd.
Conditions
Healthy
Secondary Hyperparathyroidism
Phase 1
Pharmacokinetic, Pharmacodynamic and Safety Evaluation After Single Oral Administration of KRN1493
Completed
NCT00952094
Seoul National University Hospital
Healthy
Start: 2008-11-30
End: 2009-06-30
Updated: 2009-08-04
Phase 2
Phase 2 Study of KHK7580
Completed
NCT02216656
Kyowa Kirin Co., Ltd.
Secondary Hyperparathyroidism
Start: 2014-07-31
End: 2015-02-28
Updated: 2018-07-10
Phase 3 Study of KHK7580
Completed
NCT02549391
Kyowa Kirin Co., Ltd.
Secondary Hyperparathyroidism
Start: 2015-09-30
End: 2016-11-30
Updated: 2017-03-24
Related Papers
Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism
PLoS ONE
2022-12-13
3 citations
Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism
PLoS ONE
2022-02-17
6 citations